Mankind Pharma Limited has successfully secured the reaffirmation of its credit ratings for outstanding debt instruments. Specifically, the ratings for Non-Convertible Debentures of ₹5,000 crore and Long-term/Short-term fund-based limits of ₹1,250 crore have been maintained. The reaffirmation status indicates continued confidence in the company’s financial stability and robust operational performance moving forward.
Credit Rating Reaffirmation Announcement
Mankind Pharma Limited has officially announced the reaffirmation of credit ratings for certain outstanding instruments. This disclosure follows a mandatory review process, confirming the existing positive outlook on the company’s debt profile.
Details of Rated Instruments
The confirmation applies to two primary categories of instruments, reflecting sustained credit quality:
Non-Convertible Debentures
The rating assigned to the Non-Convertible Debentures, totaling an amount of ₹5,000 crore, has been reaffirmed at the (ICRA) AA+/Stable level. The rating action taken was a Reaffirmed status.
Fund-Based Limits
For the Long-term/Short-term fund-based limits, amounting to ₹1,250 crore, the current ratings have also been maintained. These limits carry the rating of (ICRA) A1+, which remains Reaffirmed.
Management Commentary
The company stated that this reaffirmation reflects the sustained strength in its financial position and the stability observed across its operational segments. All supporting documentation and detailed rating rationales are available for review on the company’s official investor relations website.
Source: BSE
